Literature DB >> 23295737

Chronic glucocorticoid exposure potentiates placental chorionic plate artery constriction: implications for aberrant fetoplacental vascular resistance in fetal growth restriction.

J L Nugent1, M Wareing, V Palin, C P Sibley, P N Baker, D W Ray, S N Farrow, R L Jones.   

Abstract

Fetal growth restriction (FGR) is a serious pregnancy complication, resulting in significant perinatal morbidity and mortality. Increased vascular resistance in the fetoplacental circulation is a hallmark of FGR and is associated with enhanced vasoconstriction of the resistance arteries in the placenta, the chorionic plate arteries (CPAs). Although the cause is unknown, FGR is associated with excess exposure to glucocorticoids (GCs), key mediators of vascular resistance in the systemic circulation. We hypothesized that GCs alter CPA reactivity, thereby contributing to the altered blood flow dynamics seen in FGR. We aimed to examine the acute and chronic effects of GCs on CPA reactivity and the operational mechanisms. Glucocorticoid receptors were highly expressed by CPA. 11β-Hydroxysteroid isoenzyme type 2 was detected within the endothelium, whereas 11β-hydroxysteroid isoenzyme type 1 was absent. Acute GC treatment significantly attenuated U46619-induced constriction. This effect was reversed by cotreatment with mifepristone or an endothelial NOS inhibitor. In contrast, chronic GC treatment potentiated U46619 constriction in a dose-dependent manner, which was partially abolished by mifepristone cotreatment. Similar effects were observed using a novel nonsteroidal glucocorticoid receptor-specific agonist. Chronic treatment with GCs altered the expression of several vasoactive factors, including thromboxane and bradykinin receptors, prokineticin-1, cyclooxygenase-2, and endothelial NOS. In summary, acute and chronic GC treatment exerts contrasting effects on CPA vasoreactivity. These opposing effects are consistent with temporal actions in other vascular beds and reflect activation of distinct nongenomic and genomic pathways. Chronic exposure to elevated GCs may contribute to the raised vascular resistance observed in the fetoplacental circulation in FGR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23295737     DOI: 10.1210/en.2012-1927

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Intraspinal cavernous bleeding during early pregnancy.

Authors:  Kaweh Pars; Niklas Garde; Josef Conzen; Refik Pul; Reinhard Dengler; Martin Stangel; Thomas Skripuletz; Corinna Trebst
Journal:  J Neurol       Date:  2016-08-03       Impact factor: 4.849

Review 2.  Molecular and cellular underpinnings of normal and abnormal human placental blood flows.

Authors:  Yingchun Li; Ramón A Lorca; Emily J Su
Journal:  J Mol Endocrinol       Date:  2017-11-02       Impact factor: 5.098

Review 3.  Antenatal endogenous and exogenous glucocorticoids and their impact on immune ontogeny and long-term immunity.

Authors:  María Emilia Solano; Megan C Holmes; Paul R Mittelstadt; Karen E Chapman; Eva Tolosa
Journal:  Semin Immunopathol       Date:  2016-07-28       Impact factor: 9.623

4.  Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

5.  Metabolomic profile of umbilical cord blood plasma from early and late intrauterine growth restricted (IUGR) neonates with and without signs of brain vasodilation.

Authors:  Magdalena Sanz-Cortés; Rodrigo J Carbajo; Fatima Crispi; Francesc Figueras; Antonio Pineda-Lucena; Eduard Gratacós
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

6.  The Application Value of Three-Dimensional Power Doppler Ultrasound in Fetal Growth Restriction.

Authors:  Yanju Wang; Lihua Liang; Yingfeng Liu; Peipei Li; Jie Ren
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-16       Impact factor: 2.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.